TP53 and acute myeloid leukemia: Other agents actually studied in primary AML that could be potentially tested in AML-pCT patients include, among others: eprenetapopt, a small-molecule inhibitor selectively inducing apoptosis in TP53-mutated cancer cells, and flotetuzumab, a bispecific antibody binding CD123 and CD3, anti-CD123 CAR-T [14].